936251-01-3

Basic information

• Product Name: [(trans)-1-benzyl-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester
• CAS NO: 936251-01-3
• Molecular Weight: 406.448
• Mol File: 936251-01-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: [(trans)-1-benzyl-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [(trans)-1-benzyl-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester(936251-01-3)
• EPA Substance Registry System: [(trans)-1-benzyl-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester(936251-01-3)

Safety Data

• Hazardous Substances Data: 936251-01-3(Hazardous Substances Data)

Usage

General Description

The chemical [(trans)-1-benzyl-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester is a compound that belongs to the class of carbamic acid esters. It consists of a pyrrolidine ring with a benzyl and trifluorophenyl substituent, and a carbamic acid tert-butyl ester group. [(trans)-1-benzyl-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester may be used in the field of medicinal chemistry for the design and synthesis of potential pharmaceutical agents, particularly for the treatment of neurological and psychiatric disorders. Its specific chemical structure and pharmacological properties make it a potential candidate for further research and development in the pharmaceutical industry.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 165047-24-5 2,4,5-trifluorobenzaldehyde 
• 956924-25-7 2-nitro-1-(2,4,5-trifluorophenyl)ethanol 
• 915100-73-1 (3R,4S)-1-benzyl-4-(2,4,5-trifluorophenyl)pyrrolidine-3-carboxylic acid 
• 75-65-0 tert-butyl alcohol 
• 936251-05-7 C₁₇H₁₅F₃N₂O₂ 
• 915100-66-2 (E)-1,2,4-trifluoro-5-(2-nitrovinyl)benzene 
• 93102-05-7 N-benzyl-N-(methoxymethyl)-N-[(trimethylsilyl)methyl]amine 

Relevant articles and documents

1,4 DISUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS

Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR1 19. Compounds having stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.

Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit

A novel series of pyrrolidine-constrained phenethylamines were developed as dipeptidyl peptidase IV (DPP4) inhibitors for the treatment of type 2 diabetes. The cyclohexene ring of lead-like screening hit 5 was replaced with a pyrrolidine to enable paralle